Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from XXXX .

@entity1 @entity358 @entity5 @entity14
BACKGROUND: Limited data describe the prognosis after stereotactic ablative radiotherapy for lung metastases arising from @entity14 . Thus, we evaluated treatment outcomes of stereotactic ablative radiotherapy for those @entity1 . METHODS: The study involved @entity1 received stereotactic ablative radiotherapy for one to three lung metastases arising from @entity14 at a single institution. A total dose of 40-60  Gy (median, 48  Gy) in three or four fractions was prescribed. RESULTS: A total of 79 metastatic lung lesions from 50 @entity1 who underwent curative resection for their primary @entity14 or salvage treatment at a recurrent site were included. The one- and three-year local control rates were 88.7  % and 70.6  %, respectively. The three-year overall survival and progression-free survival rates were 64.0  % and 24.0  %, respectively. @entity1 with @entity5 volume  <=1.5  mL had a significantly better overall survival rate than those with @entity5 volume >1.5  mL (68.0  % vs. 60.0  % at three-year, p   =   0.02). Local control was associated with a trend towards better survival (p   =   0.06). No @entity358 greater than grade 2 were observed. CONCLUSION: Stereotactic ablative radiotherapy is a competitive treatment modality for the management of lung metastases arising from @entity14 .
